Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial

Published:2021-02 Issue:2 Volume:21 Page:263-274
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Absalon Judith,Segall Nathan,Block Stan L,Center Kimberly J,Scully Ingrid L,Giardina Peter C,Peterson James,Watson Wendy J,Gruber William C,Jansen Kathrin U,Peng Yahong,Munson Samantha,Pavliakova Danka,Scott Daniel A,Anderson Annaliesa S

Funder

Pfizer

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference25 articles.

1. An overview of global GBS epidemiology;Le Doare;Vaccine,2013

2. Epidemiology of group B streptococcus in developing countries;Johri;Vaccine,2013

3. Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010;Verani;MMWR Recomm Rep,2010

4. Maternal colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in coastal Kenya;Seale;Nat Microbiol,2016

5. Temporal changes in invasive group B streptococcus serotypes: implications for vaccine development;Dangor;PLoS One,2016

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Group B streptococcal infections;Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant;2025

2. Re-framing the importance of Group B Streptococcus as a gut-resident pathobiont;Infection and Immunity;2024-09-10

3. Maternal Streptococcus agalactiae colonization in Europe: data from the multi-center DEVANI study;Infection;2024-09-08

4. The Evolving Maternal Vaccine Platform;Reproductive Medicine;2024-08-07

5. Association of natural induced antibodies against select Group B streptococcus surface proteins and invasive disease in early infancy;2024-07-21